Currently Viewing:
Newsroom
Currently Reading
Large Review Finds Vitamin D Ineffective in Preventing Fractures, Falls
October 15, 2018 – Allison Inserro
Driver Mutations May Predict Patient Outcomes in Myeloproliferative Neoplasms
October 15, 2018 – Kelly Davio
Three Genetic Types Drive Higher Prevalence of MM in African Americans
October 14, 2018 – Laura Joszt
ACOs Had No Significant Impact on Spending for Patients With Cancer
October 14, 2018 – Laura Joszt
Analysis Estimates Empagliflozin Will Add Years to Life for People With Type 2 Diabetes
October 13, 2018 – Mary Caffrey
Study Examines Impact of Deviating From NCCN Guidelines for Metastatic Breast Cancer
October 13, 2018 – Allison Inserro
Researchers Have Found 3 Genes Linked to Chronic Back Pain
October 12, 2018 – Allison Inserro
FDA Inquiring If Some e-Cigarette Makers Are Selling Devices Without Approval
October 12, 2018 – Allison Inserro
Know the Risk: 5 Breast Cancer Risk Factors
October 12, 2018 – Samantha DiGrande

Men With Advanced Cancers Respond Better Than Women to Immune Checkpoint Inhibitors

Samantha DiGrande
A recent systematic review and meta-analysis published in The Lancet Oncology found that men with advanced cancers respond better than women to treatment with anti-PD-1 or anti-CTLA-4 immune checkpoint inhibitors.
A recent systematic review and meta-analysis published in The Lancet Oncology found that men with advanced cancers respond better than women to treatment with anti-PD-1 or anti-CTLA-4 immune checkpoint inhibitors.

Researchers identified 20 eligible randomized controlled trials of immune checkpoint inhibitors (ipilimumab, tremelimumab, nivolumab, or pembrolizumab) that reported overall survival according to patients’ sex. The 20 randomized trials were comprised of a total of 11,351 patients with advanced or metastatic cancers (7646 [67%] men and 3705 [32%] women).

The pooled overall survival hazard ratio (HR) was 0.72 (95% CI 0.65-0.79), or 28% lower risk of death in male patients treated with immune checkpoint inhibitors, compared with men treated standard therapies in control groups. In women treated with immune checkpoint inhibitors, the pooled overall survival was 0.86 (95% CI 0.79-0.93), or 14% lower risk of death compared with control groups. Researchers identified that the difference in efficacy between men and women treated with immune checkpoint inhibitors was significant, P = .0019.

“Immune checkpoint inhibitors can improve overall survival for patients with advanced cancers such as melanoma and non-small cell lung cancer, but the magnitude of benefit is sex-dependent. The pooled reduction of risk of death was double the size for male patients than for female patients,” noted the study authors. 

Based on these findings, the authors have recommended that a patient’s sex “should be taken into account in the assessment of risk versus benefit when making decisions about treatment strategies.”

Future research should look to optimize immunotherapies for female patients, and clinical trials should strive to include more women to better ensure they capture a potential therapies’ effectiveness more effectively.

As “immune checkpoint inhibitors are associated with specific adverse events, efforts are ongoing to identify predictive biomarkers” that may be able to identify patients that are most likely to “derive the maximum benefit” from a specific treatment. These efforts must be aware of “sex-related differences in the benefit[s] achievable from immunotherapies.” However, to date it “remains an under-investigated issue.”

Reference

Conforti F, Pala L, Bagnardi V, et al. Cancer immunotherapy efficacy and patients’ sex: a systematic review and meta-analysis [published online May 16, 2018]. Lancet Oncol. doi.org/10.1016/S1470-2045(18)30261-4

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!